Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

An IgG human monoclonal antibody reactive with a surface membrane antigen expressed on malignant breast cancer cells

An IgG human monoclonal antibody reactive with a surface membrane antigen expressed on malignant... A human IgG 3 monoclonal antibody (HMab), F86, that reacts with breast cancer cells was obtained by fusion of antibody-secreting Epstein-Barr virus (EBV)-transformed cells from a draining lymph node with the human fusion partner HMMA2.11TG/O. F86 reacts with an antigen expressed on the surface offive malignant human breast cancer cell lines and several human malignant myelomonocytic cell lines but is not detected on normal peripheral blood mononuclear cells. Studies with tissue sections of a human breast cancer line xenografted in nude mice have demonstrated that the F86 antigen is expressed both on the cell surface and in the cytoplasm of tumor cells. The F86 antigen is also expressed by the tumor cells in the original tumor specimen of a patient from whom one of the test cell lines and the xenografts were derived. Functionally, the F86 antibody does not mediate complement lysis or antibody-dependent cellular cytotoxicity in vitro. The F86 antigen could not be labeled by ( 35 S)methionine or 125 I and immunoprecipitated. The nature and expression of antigens such as that detected by the HMab F86 and how they became immunogenic and/or suppress an active immune response can be addressed through the use of HMab. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Human Antibodies IOS Press

An IgG human monoclonal antibody reactive with a surface membrane antigen expressed on malignant breast cancer cells

Loading next page...
 
/lp/ios-press/an-igg-human-monoclonal-antibody-reactive-with-a-surface-membrane-1vh00h1iAh

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 1991 by IOS Press, Inc
ISSN
1093-2607
eISSN
1875-869X
DOI
10.3233/HAB-1991-2205
Publisher site
See Article on Publisher Site

Abstract

A human IgG 3 monoclonal antibody (HMab), F86, that reacts with breast cancer cells was obtained by fusion of antibody-secreting Epstein-Barr virus (EBV)-transformed cells from a draining lymph node with the human fusion partner HMMA2.11TG/O. F86 reacts with an antigen expressed on the surface offive malignant human breast cancer cell lines and several human malignant myelomonocytic cell lines but is not detected on normal peripheral blood mononuclear cells. Studies with tissue sections of a human breast cancer line xenografted in nude mice have demonstrated that the F86 antigen is expressed both on the cell surface and in the cytoplasm of tumor cells. The F86 antigen is also expressed by the tumor cells in the original tumor specimen of a patient from whom one of the test cell lines and the xenografts were derived. Functionally, the F86 antibody does not mediate complement lysis or antibody-dependent cellular cytotoxicity in vitro. The F86 antigen could not be labeled by ( 35 S)methionine or 125 I and immunoprecipitated. The nature and expression of antigens such as that detected by the HMab F86 and how they became immunogenic and/or suppress an active immune response can be addressed through the use of HMab.

Journal

Human AntibodiesIOS Press

Published: Jan 1, 1991

There are no references for this article.